enGene (ENGN) Competitors $6.50 -0.48 (-6.88%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$6.50 +0.00 (+0.08%) As of 09/25/2025 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. PGEN, WVE, NUVB, ORIC, AMLX, MAZE, SION, PHAR, TRVI, and ATAIShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Precigen (PGEN), WAVE Life Sciences (WVE), Nuvation Bio (NUVB), Oric Pharmaceuticals (ORIC), Amylyx Pharmaceuticals (AMLX), Maze Therapeutics (MAZE), Sionna Therapeutics (SION), Pharming Group (PHAR), Trevi Therapeutics (TRVI), and atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry. enGene vs. Its Competitors Precigen WAVE Life Sciences Nuvation Bio Oric Pharmaceuticals Amylyx Pharmaceuticals Maze Therapeutics Sionna Therapeutics Pharming Group Trevi Therapeutics atai Life Sciences Precigen (NASDAQ:PGEN) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Is PGEN or ENGN more profitable? enGene has a net margin of 0.00% compared to Precigen's net margin of -2,868.66%. enGene's return on equity of -39.86% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Precigen-2,868.66% -842.83% -78.98% enGene N/A -39.86%-34.15% Which has more volatility and risk, PGEN or ENGN? Precigen has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. Does the media prefer PGEN or ENGN? In the previous week, Precigen had 9 more articles in the media than enGene. MarketBeat recorded 12 mentions for Precigen and 3 mentions for enGene. Precigen's average media sentiment score of 0.41 beat enGene's score of 0.01 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, PGEN or ENGN? enGene has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$3.92M264.52-$126.24M-$0.42-8.29enGeneN/AN/A-$55.14M-$1.90-3.42 Do institutionals and insiders hold more shares of PGEN or ENGN? 33.5% of Precigen shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 47.1% of Precigen shares are held by company insiders. Comparatively, 10.4% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate PGEN or ENGN? Precigen currently has a consensus price target of $8.25, suggesting a potential upside of 137.07%. enGene has a consensus price target of $19.50, suggesting a potential upside of 200.00%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than Precigen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80enGene 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryenGene beats Precigen on 10 of the 16 factors compared between the two stocks. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$357.32M$3.13B$5.74B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-3.4220.6375.7726.11Price / SalesN/A442.69544.59124.93Price / CashN/A44.6737.5461.24Price / Book1.669.6212.876.30Net Income-$55.14M-$52.73M$3.29B$271.03M7 Day Performance-4.69%1.81%0.26%-0.14%1 Month Performance49.08%5.50%2.85%5.82%1 Year Performance18.18%18.12%65.65%27.63% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene2.5817 of 5 stars$6.50-6.9%$19.50+200.0%+4.0%$357.32MN/A-3.4231PGENPrecigen4.4064 of 5 stars$3.59-5.3%$8.25+129.8%+276.8%$1.13B$3.92M-8.55190WVEWAVE Life Sciences4.4543 of 5 stars$6.97flat$20.33+191.7%-26.1%$1.11B$108.30M-7.74240NUVBNuvation Bio2.714 of 5 stars$3.14flat$7.50+138.9%+25.7%$1.07B$7.87M-4.9860Gap DownORICOric Pharmaceuticals4.374 of 5 stars$10.71-0.6%$17.29+61.4%+4.1%$1.04BN/A-5.6780Insider TradeAMLXAmylyx Pharmaceuticals1.2383 of 5 stars$11.85+1.7%$13.25+11.8%+342.9%$1.04B$87.37M-4.74200MAZEMaze Therapeutics3.3328 of 5 stars$23.25-0.2%$32.67+40.5%N/A$1.02B$167.50M0.00121SIONSionna Therapeutics2.6023 of 5 stars$22.31-2.3%$38.00+70.3%N/A$1.01BN/A0.0035PHARPharming Group2.2354 of 5 stars$13.72-6.6%$30.00+118.7%+92.2%$1.01B$297.20M-105.50280TRVITrevi Therapeutics2.2906 of 5 stars$8.06-2.3%$21.75+169.9%+174.7%$1.00BN/A-19.1920ATAIatai Life Sciences3.2067 of 5 stars$4.65+0.4%$11.25+141.9%+338.1%$992.39M$310K-6.7480Analyst ForecastGap Down Related Companies and Tools Related Companies PGEN Competitors WVE Competitors NUVB Competitors ORIC Competitors AMLX Competitors MAZE Competitors SION Competitors PHAR Competitors TRVI Competitors ATAI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
